Multitude Therapeutics
Multitude Therapeutics is a China-based biotechnology company running 4 late-stage cancer trials of AMT-116, AMT-676 and AMT-253 in colorectal cancer, melanoma and non-small-cell lung cancer.
Overview
Multitude Therapeutics, based in Shanghai, China, is a biotechnology company. Multitude Therapeutics is a clinical-stage biotechnology company in China developing antibody-drug conjugate therapies for cancer, using its PAD molecular design platform and MabArray target discovery platform. On ClinicalTrials.gov it is the lead sponsor of 4 recruiting or active phase 2 and phase 3 interventional cancer trials, testing AMT-116, AMT-676, AMT-253 and AK112 in colorectal cancer, melanoma and non-small-cell lung cancer. The largest, NCT07474727 (A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer), plans to enrol 180 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanyKrystal Biotech
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanymAbxience Research S.L.
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanySTCube
Shares Colorectal cancer, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyVyriad
Shares Melanoma, Colorectal cancer, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyShanghai Kechow Pharma
Shares Melanoma, Colorectal cancer and the tag ctgov-sponsor.
- CompanyiOnctura
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyGeorgiamune
Shares Melanoma and the tag ctgov-sponsor.
- CompanyShanghai Juncell Therapeutics
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.